Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, ...

Moderna Inc.’s stock reached a 52-week low, closing at 23.04 USD, reflecting a significant downturn over the past year. The biotech company’s shares have experienced a substantial decline, with a year ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This ...

Moderna ( ($MRNA) ) just unveiled an update. On November 19, 2025, Moderna, Inc. entered into a Credit and Guaranty Agreement providing a $1.5 ...

The biotechnology firm announced it aims to achieve up to 10% revenue growth in 2026 while working toward cash breakeven by 2028. Moderna plans to expand its seasonal vaccine franchise from three to ...

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year ...

The Dow Jones Industrial Average edged down 0.8% to 45,752.26, while the S&P 500 dropped 1.56% to 6,538.76 and the Nasdaq ...

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 24.6% and a 57.3% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Monte Rosa ...

Telemark Asset Management, LLC established a new position in Moderna ( MRNA +1.10%), acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November ...